On September 26, the FDA approved Cobenfy, the first schizophrenia treatment in nearly three decades, which offers a novel mechanism of action targeting the cholinergic system.
Developed by Karuna Therapeutics, Cobenfy represents a significant shift from existing schizophrenia medications, which predominantly affect the dopamine system, generating hope among patients and clinicians.
By leveraging research on muscarinic receptors initially explored for Alzheimer's, scientists were able to create Cobenfy, which specifically targets the cholinergic system, potentially minimizing side effects.
Andrew Miller's innovative approach combined xanomeline with a retrofitted drug to selectively activate the muscarinic system in the brain while suppressing it in other areas, showcasing a remarkable advancement.
Collection
[
|
...
]